Fennec Pharmaceuticals Inc.

Good morning, ladies and gentlemen, and welcome to FENIC Pharmaceuticals Second Quarter 2026 Earnings and Corporate Update Conference Call. At this time, all participants are in listen-only mode. Later, we'll conduct a question and answer session, and instructions on how to participate will be given at that time. As a reminder, today's conference call is being recorded. Now, I'd like to turn the conference over to FENIC's Chief Financial Officer, Robert Andrade.

Thank you, Operator, and good morning, everyone. We would like to thank you for joining us. We are pleased to host Fennec Pharmaceuticals' second quarter 2026 earnings conference call today, during which we will review our financial results, as well as provide a general business update. Joining me from Fennec this morning is our chief executive officer and board member, Jeff Hackman, our chief commercial officer, Terry Evans, and our chief medical officer, Dr. Pierre Sayad. I am also pleased to welcome our Chief Strategy Officer, Christy Cioffi, who is joining our earnings call for the first time. Christy has more than two decades of leadership experience spanning commercial strategy, brand building, and organizational development, including nearly 15 years of expertise leading award-winning commercialization and launch strategies across the product lifecycle. She has held senior commercial leadership roles at a number of leading biopharmaceutical companies, including Shield Therapeutics, Stemline Therapeutics, Yusa Pharma, CarioPharm Therapeutics, Servier, previously Shire, Exalta, Baxter, and Abbott Laboratories, where she helped build and grow oncology, rare disease, and hematology brands from early development through commercialization. As a graduate of West Point, Christy also served our country as a decorated U.S. Army veteran and Bronze Star recipient, leading soldiers during two deployments in Operation Iraqi Freedom. Later in the call, Christy will speak to how recent cross-functional efforts are supporting our long-term growth plans. Additionally, Dr. Pierre Sayad will provide a medical affairs update and Terry Evans will speak to our commercial progress. Before we begin, I would like to remind you that during this call, the company will be making forward looking statements that are subject to risks and uncertainties that may cause actual results to differ from the results discussed in the forward looking statements. Reference to these risks and uncertainties are made in today's press release and disclosed in detail in the company's periodic and current event filings with the United States Securities and Exchange Commission. In addition, any forward-looking statements made on this call represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update or revise any forward-looking statements. This conference call is being recorded for audio rebroadcast on Fennec's website, www.fennecpharma.com, where it will be available for the next 30 days. I will now turn the call over to Jeff Hackman.

Thank you, Robert, and good morning, everyone. Thank you all for joining us here today. So before we dive into the quarter, I'd like to take a moment to reflect on how far we've come as an organization. Two years ago, I joined Fennec with clear objectives, build the team, sharpen our execution, and position the company for sustainable long-term growth. Over that time, we've built a talented and experienced leadership team, deep expertise across commercial, medical affairs, clinical development, and corporate strategy. Today, you'll have the opportunity to hear from each of them about the progress that they're making in their business. We also expanded our customer-facing team, as you know, to reach a larger prescriber target base with a greater frequency, increasing the numbers from 1,300 to roughly 5,000 targets. Together, we built an organization that is focused, accountable, and aligned around delivering for our patients, our healthcare providers, and our shareholders. I'm proud of what we accomplished. Since I joined the company, we've increased revenue by 143%, driven by a unified strategy, consistent execution, and a disciplined focus on the fundamentals of our business. Perhaps most importantly, we've demonstrated that this isn't the result of any single initiative or quarter. It's been built through steady execution, expanding our commercial reach, strengthening our clinical evidence base, investing in targeted, Thank you. Thank you. that make life most meaningful. While we're proud of our progress, we also believe we're still in the early stages of our opportunity. As you'll hear today, we're continuing to invest in the drivers that we believe will support long-term growth. From generating additional clinical evidence and expanding physician engagement to building awareness and ensuring that we have resources to execute on our strategies. One of those drivers in Q2 was breaking new ground in a disease awareness campaign, bringing the conversation around testicular cancer to the Indianapolis 500 and introducing Phenic and our mission to millions of fans and forging meaningful connections across the oncology community. Christy will go much deeper into detail and the impact of this campaign shortly. As a reminder, Pedmark is currently approved for pediatric patients one month of age and older with localized non-metastatic solid tumors and is also recognized by the National Comprehensive Cancer Network with the 2A recommendations for use in AYA patients. As we look ahead, we believe the investments we've made across our commercial organization, the clinical evidence generation efforts, and the financial foundation is translating into meaningful momentum. Encouraged by what we've seen so far in the third quarter, we are confident in our ability to continue to build on this progress and deliver sustainable growth. So with that, I'll turn it over to Christy for a more detailed update on our disease awareness efforts and our presence at ASCO.